Literature DB >> 31993493

RAS-driven oncogenesis is supported by downstream antioxidant programs.

Jonathan K M Lim1, Gabriel Leprivier1, Poul H Sorensen2,3.   

Abstract

In our recent study, we demonstrated that oncogenic RAS (rat sarcoma)-mediated transformation and tumorigenesis are supported by transcriptional induction of a crucial antioxidant component, SLC7A11 (solute carrier family 7 member 11), otherwise known as XCT, a gene encoding the cystine/glutamate transporter. Our data highlight that this promotes the biosynthesis of glutathione, in turn allowing RAS transformed cells to mitigate tumorigenesis-linked oxidative stress.
© 2019 Taylor & Francis Group, LLC.

Entities:  

Year:  2019        PMID： 31993493      PMCID： PMC6961675          DOI： 10.1080/23723556.2019.1654814

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  Redox imbalance in cystine/glutamate transporter-deficient mice.

Authors:  Hideyo Sato; Ayako Shiiya; Mayumi Kimata; Kanako Maebara; Michiko Tamba; Yuki Sakakura; Nobuo Makino; Fumihiro Sugiyama; Ken-ichi Yagami; Takashi Moriguchi; Satoru Takahashi; Shiro Bannai
Journal:  J Biol Chem       Date:  2005-09-06       Impact factor: 5.157

2.  Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.

Authors:  Isaac S Harris; Aislinn E Treloar; Satoshi Inoue; Masato Sasaki; Chiara Gorrini; Kim Chung Lee; Ka Yi Yung; Dirk Brenner; Christiane B Knobbe-Thomsen; Maureen A Cox; Andrew Elia; Thorsten Berger; David W Cescon; Adewunmi Adeoye; Anne Brüstle; Sam D Molyneux; Jacqueline M Mason; Wanda Y Li; Kazuo Yamamoto; Andrew Wakeham; Hal K Berman; Rama Khokha; Susan J Done; Terrance J Kavanagh; Ching-Wan Lam; Tak W Mak
Journal:  Cancer Cell       Date:  2015-01-22       Impact factor: 31.743

3.  Ferroptosis: an iron-dependent form of nonapoptotic cell death.

Authors:  Scott J Dixon; Kathryn M Lemberg; Michael R Lamprecht; Rachid Skouta; Eleina M Zaitsev; Caroline E Gleason; Darpan N Patel; Andras J Bauer; Alexandra M Cantley; Wan Seok Yang; Barclay Morrison; Brent R Stockwell
Journal:  Cell       Date:  2012-05-25       Impact factor: 41.582

4.  Differential Requirements for eIF4E Dose in Normal Development and Cancer.

Authors:  Morgan L Truitt; Crystal S Conn; Zhen Shi; Xiaming Pang; Taku Tokuyasu; Alison M Coady; Youngho Seo; Maria Barna; Davide Ruggero
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

5.  The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation.

Authors:  Junji Mitsushita; J David Lambeth; Tohru Kamata
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

6.  Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.

Authors:  Jihye Yun; Edouard Mullarky; Changyuan Lu; Kaitlyn N Bosch; Adam Kavalier; Keith Rivera; Jatin Roper; Iok In Christine Chio; Eugenia G Giannopoulou; Carlo Rago; Ashlesha Muley; John M Asara; Jihye Paik; Olivier Elemento; Zhengming Chen; Darryl J Pappin; Lukas E Dow; Nickolas Papadopoulos; Steven S Gross; Lewis C Cantley
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

7.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

Authors:  Gina M DeNicola; Florian A Karreth; Timothy J Humpton; Aarthi Gopinathan; Cong Wei; Kristopher Frese; Dipti Mangal; Kenneth H Yu; Charles J Yeo; Eric S Calhoun; Francesca Scrimieri; Jordan M Winter; Ralph H Hruban; Christine Iacobuzio-Donahue; Scott E Kern; Ian A Blair; David A Tuveson
Journal:  Nature       Date:  2011-07-06       Impact factor: 49.962

8.  A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

Authors:  Judith G Villablanca; Samuel L Volchenboum; Hwangeui Cho; Min H Kang; Susan L Cohn; Clarke P Anderson; Araz Marachelian; Susan Groshen; Denice Tsao-Wei; Katherine K Matthay; John M Maris; Charlotte E Hasenauer; Scarlett Czarnecki; Hollie Lai; Fariba Goodarzian; Hiro Shimada; Charles Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2016-04-19       Impact factor: 3.167

9.  Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.

Authors:  Emma M Kerr; Edoardo Gaude; Frances K Turrell; Christian Frezza; Carla P Martins
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962
  9 in total
  1 in total

Review 1.  The Role of SLC7A11 in Cancer: Friend or Foe?

Authors:  Sijia Li; Zhenyao Lu; Runbin Sun; Suhan Guo; Fangfang Gao; Bei Cao; Jiye Aa
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.